Impact of the Inflation Reduction Act for Emerging Biopharma
Join us for this webinar where we’ll look beyond the specific changes laid out in the Inflation Reduction Act (IRA) of 2022 and explore the second and third order effects and how they’ll play out over the next decade. Our IQVIA industry experts, Luke Greenwalt and Mason Tenaglia, will discuss how emerging biopharma companies (EBPs) can navigate through these changes to optimize their product performance.
Key takeaways:
How EBPs can best prepare for the changes and risks resulting from the IRA as they play out over the next decade
How to gauge the impact of different actions (and inactions) on a portfolio, short and long term
The potential impact for EBP companies related to market access, organizational strategy, gross-to-net economics, and financial strategy